Cherubism is an autosomal-dominant syndrome characterized by inflammatory destructive bony lesions resulting in symmetrical deformities of the facial bones. Cherubism is caused by mutations in Sh3bp2, the gene that encodes the adaptor protein 3BP2. Most identified mutations in 3BP2 lie within the peptide sequence RSPPDG. A mouse model of cherubism develops hyperactive bone-remodeling osteoclasts and systemic inflammation characterized by expansion of the myelomonocytic lineage. The mechanism by which cherubism mutations alter 3BP2 function has remained obscure. Here we show that Tankyrase, a member of the poly(ADP-ribose) polymerase (PARP) family, regulates 3BP2 stability through ADP-ribosylation and subsequent ubiquitylation by the E3-ubiquitin ligase RNF146 in osteoclasts. Cherubism mutations uncouple 3BP2 from Tankyrase-mediated protein destruction, which results in its stabilization and subsequent hyperactivation of the SRC, SYK, and VAV signaling pathways.
INTRODUCTION
Cherubism is a dominantly inherited disorder characterized by facial disfigurement, early tooth loss, failure of permanent tooth eruption, and distortion of the orbital socket creating an upturned eye appearance occasionally associated with blindness (Jones et al., 1950) . Interosseous fibrocystic lesions arise in cherubism patients as a result of highly activated osteoclasts and infiltrating inflammatory and mesenchymal cells. The cherubism locus was mapped to chromosome 4p16 (Tiziani et al., 1999) with subsequent identification of single missense mutations in the gene encoding the adaptor protein 3BP2 within this locus (Ueki et al., 2001 ). 3BP2 contains an N-terminal pleckstrin homology (PH) domain, a proline-rich stretch that binds to Src homology (SH) 3 domain-containing proteins, and a C-terminal SH2 domain that binds to phosphotyrosine residues (Deckert, 2006) (Figure 1D ). Most 3BP2 mutations associated with cherubism cluster within peptide sequence RSPPDG lying between the PH and SH2 domains. A mouse model of cherubism in which the most common disease-associated allele, P416R, was knocked into the Sh3bp2 locus develops severe osteoporosis associated with highly activated osteoclasts and demonstrated that mutation within this peptide sequence results in a gain-of-function phenotype (Ueki et al., 2007) . Analysis of mice harboring two copies of the cherubism allele uncovered 3BP2 as a major governor of myelomonocytic homeostatic cell numbers. Homozygous mice die of a systemic inflammation disorder at 25 weeks of age as a result of myelomonocytic infiltration of the skin, synovial lining, and visceral organs associated with elevated serum TNF-a levels, trabecular bone loss, and cortical bone erosions (Ueki et al., 2007) .
3BP2 was originally identified as a binding protein of the tyrosine kinase ABL SH3 domain through proline-rich sequences lying between the PH and SH2 domains (Cicchetti et al., 1992) . 3BP2 is part of a multiprotein signaling complex composed of the SRC family kinases (SFKs), SYK, and the RHO family guanine nucleotide exchange factor VAV (Deckert and Rottapel, 2006) and is required for optimal B cell antigen receptor (Chen et al., 2007; de la Fuente et al., 2006) and integrin activation (Levaot et al., 2011) . The biochemical basis by which cherubism mutations alter the activity of the 3BP2 adaptor protein has remained elusive. The tight cluster of mutations in the peptide sequence of 3BP2 observed in cherubism patients suggested to us that this sequence might define a protein interaction motif.
Here we identify the poly(ADP-ribose)polymerase (PARP) family member Tankyrase as the protein that binds to the RSPPDG sequence and serves to repress 3BP2 protein levels through ADP-ribosylation and subsequent ubiquitylation by the E3-ubiquitin ligase RNF146. We demonstrate that cherubism mutations disrupt 3BP2 binding to Tankyrase and stabilize the Proteins were separated by SDS-PAGE and visualized by autoradiography. (B) The PARP inhibitor PJ-34 inhibits TNKS2-dependent ribosylation of 3BP2. Flag-3BP2 immune complexes were subjected to an in vitro PARP reaction in the presence of increasing concentration of PJ-34. Lower panel, quantified inhibition of TNKS2 PARP activity by PJ-34, as evaluated by Myc-TNKS2 autoribosylation. (C) 3BP2 but not cherubism mutants of 3BP2 are ribosylated by TNKS2. Flag-3BP2 or Flag-3BP2 cherubism mutants were subjected to an in vitro PARP reaction. Ribosylation was measured by autoradiography. 3BP2 protein. Our accompanying manuscript (Guettler et al., 2011 [this issue of Cell] ) provides the structural basis of 3BP2 peptide recognition by the ankyrin repeats of Tankyrase, a mechanism shared by all known Tankyrase substrates. The structural insights enable us to rationalize how cherubism mutations allow 3BP2 to escape recruitment by Tankyrase. Elevated steady-state protein levels of 3BP2 observed in primary osteoclasts derived from cherubism mutant mice are associated with high levels of SRC, SYK, and VAV activity, whereas osteoclasts lacking 3BP2 are unable to normally activate SRC, SYK, and VAV. Lastly, we show that inhibition of Tankyrase in osteoclasts in vitro or depletion of Tankyrase in vivo recapitulates many of the phenotypic features of cherubism. These genetic and pharmacologic experiments provide direct evidence that Tankyrase is a negative regulator of the SRC signaling pathway through its action on 3BP2. Our study elucidates the biochemical basis underlying the pathogenesis of cherubism and uncovers Tankyrase as a previously unknown component of a regulatory pathway controlling bone homeostasis and inflammatory cytokine production.
RESULTS

Cherubism Mutations Increase 3BP2 Protein Stability
We examined the levels of 3BP2 protein expressed in osteoclast progenitors, primary bone marrow-derived macrophages from wild-type (WT) mice ( Figure 1A , lanes 1 and 2) or mice harboring one (Sh3bp2 KI/+ ) ( Figure 1A , lanes 3 and 4) or two alleles (Sh3bp2 KI/KI ) ( Figure 1A , lanes 5 and 6) of the cherubism mutation P416R. Strikingly, the steady-state level of 3BP2 was increased in macrophages derived from both the hetero-and homozygote cherubism mutant mice. Quantitative PCR indicated that the levels of sh3bp2 mRNA in macrophages were similar between the three different mice strains ( Figure 1B ). This observation raised the possibility that cherubism arises as a result of a gainof-function mutation leading to the accumulation of 3BP2 protein.
To determine whether the cherubism mutation altered the stability of 3BP2, we performed a cycloheximide chase experiment on WT-or Sh3bp2 KI/KI -derived bone marrow macrophages. As shown in Figure 1C , the half-life of the WT 3BP2 protein was 6.5 hr compared to 31.4 hr for the cherubism mutant form of the protein. These data demonstrate that the P416R cherubism mutation increases the protein stability of 3BP2.
3BP2 Binds to Tankyrase, an Interaction Disrupted by Cherubism Mutations
We conjectured that the 3BP2-RSPPDG sequence might define a docking site for a negative regulatory protein responsible for controlling 3BP2 protein levels and that docking is impaired by the cherubism mutations. We used the yeast two-hybrid system with full-length 3BP2 as bait to identify 3BP2-binding proteins from a hematopoietic cell library. From this screen we identified Tankyrase 2 (TNKS2) as a potential 3BP2-interacting protein.
TNKS2 is a member of the PARP family of proteins, which catalyze the addition of ADP-ribose from NAD + to acceptor proteins. TNKS2 is most closely related to Tankyrase 1 (TNKS), a protein originally identified as a repressor of the telomerase inhibitor TRF1/TERF1 (Smith et al., 1998) . TNKS and TNKS2 contain five ankyrin repeat clusters (ARCs, see accompanying manuscript [Guettler et al., 2011] ), a sterile-alpha motif (SAM) domain mediating multimerization, and the PARP catalytic domain ( Figure 1D ).
We showed that epitope-tagged versions of both TNKS and TNKS2 bind to 3BP2 in transfected HEK293T cells ( Figure 1E ). We next tested the capacity of 3BP2 proteins harboring any one of three independent cherubism mutations within the RSPPDG motif, R413Q, P416H, or G418R, to bind to TNKS2 and showed that none of the cherubism mutants were able to bind to TNKS2 ( Figure 1F , lane 5-7). In contrast, a mutant form of 3BP2 that contains a mutation in its SH2 domain (R486K), rendering it unable to bind to phosphotyrosine-containing proteins (Sada et al., 2002) , bound to TNKS2 comparably to the WT protein ( Figure 1F , lane 4). These data demonstrate that the cherubism mutations disrupt binding between 3BP2 and TNKS2.
A recombinant GST-fusion protein containing the 3BP2 RSPPDG six amino acid sequence (GST-Hex) immobilized on glutathione Sepharose was sufficient to recruit TNKS2 from HEK293T cell lysates ( Figure 1G , lane 5) but not resin alone or resin coupled to GST ( Figure 1G, lanes 3 and 4) . However, GST-Hex peptides containing any of the three cherubism mutations failed to interact with TNKS2 ( Figure 1G , lanes 6-8). These data and those presented in Figure 1F show that the RSPPDG sequence in 3BP2 mutated in cherubism patients is both necessary and sufficient to mediate binding with TNKS2.
We mapped the interaction between 3BP2 and TNKS2 by deletion mutagenesis. TNKS2 constructs lacking either the first or the second half of the ankyrin region bound to 3BP2, whereas binding was lost when the entire ankyrin region was deleted ( Figure S1 available online). This suggests that 3BP2 likely binds to more than one of the ARCs in TNKS2 as confirmed in our accompanying manuscript (Guettler et al., 2011) . The interaction between 3BP2 and TNKS2 was not dependent on the SAM domain ( Figure S1 ). Using fluorescence polarization, we quantified binding between the recombinant N-terminal region of TNKS2 containing all five ARCs and the 3BP2 Tankyrase-targeting peptide and determined a dissociation constant of 0.5 ± 0.1 mM (see Guettler et al., 2011) .
Wild-Type 3BP2 but Not 3BP2 Cherubism Mutants Are Ribosylated by Tankyrase To determine whether 3BP2 is a TNKS2 substrate, we performed an in vitro ribosylation assay. Radioactive [ 32 P]NAD + was added as a source of ADP-ribose to 3BP2 immune complexes precipitated from HEK293T cells overexpressing TNKS2 and 3BP2. The reaction was resolved by SDS-PAGE and revealed by autoradiography. We observed two bands corresponding to the size of 3BP2 ($80 kDa) and TNKS2 ($120 kDa), respectively, or a yet to be identified copurifying protein ( Figure 2A , lane 2). Ribosylation was much stronger for the higher-molecular-weight (D) Ribosylated TNKS2 is present in 3BP2 but not cherubism mutant protein complexes. Flag-3BP2 and Myc-TNKS2 were coexpressed in HEK293T cells. Flag-3BP2 protein complexes were dissociated in 1% SDS heated to 68 C then subjected to reprecipitation with an anti-Myc antibody and probed with an anti-PAR antibody.
(E) Endogenous 3BP2 but not a cherubism mutant is ribosylated in primary osteoclasts. Western blots of 3BP2 immune complexes derived from WT or Sh3bp2 KI/KI bone marrow-derived osteoclasts were probed with anti-PAR-specific antibodies. See also Figure S2 . species compared to the lower-molecular-weight protein and was dependent on an intact TNKS2 SAM and PARP domain (Figure 2A, lanes 3 and 4) . Addition of the PARP inhibitor PJ-34 (10 mM) at a concentration above the half-maximal inhibitory concentration (IC 50 ) for Tankyrase was sufficient to inhibit ribosylation of both the lower-and higher-molecular-weight ribosylated species ( Figure 2B, lane 3) .
To determine the effect of the cherubism mutation on 3BP2 ribosylation, we subjected three mutant forms of 3BP2, R413Q, P416H, or G418R, derived from cherubism patients to an in vitro ribosylation assay. Whereas WT 3BP2 and TNKS2 formed a complex and were ribosylated ( Figure 2C , lane 3), none of the three cherubism mutants bound to TNKS2 nor became ribosylated ( Figure 2C , lanes 4-6), suggesting that the biochemical defect observed in cherubism may result from the failure of 3BP2 to bind to TNKS2 and be modified by ADP-ribose conjugation.
To confirm the identity of the ribosylated 120 kDa species present in 3BP2 immune complexes, we dissociated proteins in 1% heated SDS, reprecipitated TNKS2, and probed the immunoprecipitates with either an antibody that recognizes ADPribose (PAR) or an anti-TNKS2 antibody. We confirmed that TNKS2 is autoribosylated in 3BP2 immune complexes (Figure 2D , lane 3) but not in cherubism mutant 3BP2 protein complexes ( Figure 2D , lanes 4-6).
We next sought to determine whether endogenous 3BP2 is ribosylated in primary osteoclasts. 3BP2 immune complexes derived from WT or Sh3bp2 KI/KI osteoclasts were probed with the anti-PAR antibody. We observed that endogenous 3BP2 was ribosylated and was associated with an abundantly ribosylated protein with a molecular weight similar to TNKS2 and highmolecular-weight ribosylated species of unknown identity. Ribosylation was dramatically reduced in 3BP2 protein complexes derived from osteoclasts obtained from cherubism mice (Figure 2E) . Again we noticed that the level of 3BP2 protein present in the Sh3bp2 KI/KI -derived osteoclasts was significantly elevated compared to the WT controls ( Figure 2E , row 2). We showed that an N-terminal fragment of 3BP2 containing the RSPPDG sequence and a C-terminal fragment beginning with the RSPPDG sequence were both ribosylated by Tankyrase, showing that 3BP2 is either modified at multiple sites throughout the protein, or a single ribosylation site lies in the 13 amino acid stretch common to both constructs ( Figure S2A ). Although we found that the Tankyrase-binding sequence in 3BP2 is sufficient for the recruitment of Tankyrase (see above), it remained possible that its position in 3BP2 contributes to Tankyrase recruitment and/or ribosylation. To determine the positional effects of the Tankyrase-binding sequence on 3BP2 stability and ribosylation, we created a chimeric protein in which the nonmutated RSPPDG sequence was added to the C terminus of the cherubism mutant 3BP2R413Q. Tankyrase was able to bind to the chimeric protein but was unable to alter the steady-state levels of the chimeric protein or induce ribosylation ( Figures S2B-S2D ). These data suggest that 3BP2 ribosylation and destabilization are sensitive to the position of the Tankyrase-binding sequence in 3BP2.
Ribosylation of the Wild-Type but Not a Cherubism Mutant Form of 3BP2 by TNKS2 Induces 3BP2 Ubiquitylation and Subsequent Degradation We investigated whether TNKS2 could directly regulate 3BP2 protein levels. Wild-type 3BP2 or the cherubism mutant 3BP2R413Q was coexpressed with increasing amounts of the TNKS2 expression vector. We observed that whereas the steady-state level of 3BP2 was inversely related to TNKS2 protein level, the 3BP2R413Q mutant was resistant to the effects of TNKS2 overexpression ( Figure S3A ). To determine whether the PARP domain was required for TNKS2-induced 3BP2 destabilization, we repeated the experiment with a PARP domaindeleted mutant form of TNKS2. Although TNKS2DPARP and 3BP2 formed a complex (see Figure S3B , row 3), 3BP2 protein levels were unaffected by increasing levels of TNKS2DPARP ( Figure S3B ). These data show that the ability of TNKS2 to perturb 3BP2 protein levels is not a result of binding alone but requires the intact TNKS2 catalytic domain.
We sought to elucidate the mechanism underlying the regulation of 3BP2 protein stability by TNKS2. Conceivably, TNKS2-mediated ribosylation could mark 3BP2 for ubiquitylation and subsequent proteasome-mediated degradation. To test this possibility, we coexpressed 3BP2 and TNKS2 in the absence or presence of proteasome inhibitors. We observed that the diminished steady-state levels of 3BP2 resulting from coexpression of TNKS2 were reversed in the presence of proteasome inhibitors ( Figure 3A) . We noticed that TNKS2 levels were diminished when coexpressed with WT 3BP2 but not cherubism mutants ( Figures 1E, 1F , 2C, and 2D), suggesting that both components of the complex are rendered unstable by the interaction and stabilized by proteasome inhibition. We sought to determine whether endogenous 3BP2 was ubiquitylated in response to TNKS2 expression. A tagged version of ubiquitin was expressed in cells in the presence or absence of ectopically expressed TNKS2. Endogenous 3BP2 was then immunoprecipitated and probed by western blotting for ubiquitin modification. Whereas little ubiquitin was detected in 3BP2 immunoprecipitates in the absence of TNKS2, intense ubiquitylation of proteins present in the 3BP2 complex, seen as a diffuse smear, was induced when TNKS2 was coexpressed ( Figure 3B , lane 2 versus lane 4).
(E) Binding of RNF146 to 3BP2 is ADP-ribosylation dependent. Flag-3BP2 or Flag-3BP2R413Q immune complexes derived from cells cultured in the presence of Tankyrase inhibitor XAV-939 were probed for HA-RNF146 or Myc-TNKS2. (F) Ubiquitylation of 3BP2 requires the ring finger and the WWE domain of RNF146. HA-RNF146 but not HA-RNF146DWWE or HA-RNF146DRF mutants induce 3BP2 ubiquitylation. HA-RNF146, HA-RNF146DWWE, or HA-RNF146DRF were coexpressed with Flag-3BP2 and Myc-TNKS2. Flag-3BP2 immune complexes were probed with anti-UbK48-specific antibodies. (G) Depletion of RNF146 stabilizes 3BP2 protein levels. HEK293T cells were transfected with one of three individual shRNAs targeting RNF146 (shRNF1-3) or two nonspecific shRNAs. Endogenous 3BP2 and actin proteins were probed by western blot. See also Figure S3 . To determine whether TNKS2 PARP activity was required to stimulate 3BP2 ubiquitylation, we repeated the experiment in the presence of the nonselective PARP inhibitor PJ-34 and observed that the TNKS2 induction of 3BP2 ubiquitylation was blocked ( Figure 3B , lanes 5 and 6). We confirmed that 3BP2 is itself ubiquitylated, by a precipitation-reprecipitation experiment under denaturing conditions ( Figure S3C ). These data show that endogenous 3BP2 ubiquitylation is stimulated by TNKS2 and requires PARP activity.
To ascertain the form of TNKS2-dependent ubiquitin modification of 3BP2, we used a monoclonal antibody, which recognizes lysine 48 (Ub-K48), and observed that TNKS2 induced intense stepwise K48 ubiquitin modification, likely of 3BP2 ( Figure 3C , lane 2). To determine the effect of the cherubism mutation on 3BP2 ubiquitylation, we expressed WT 3BP2 or the cherubism mutant 3BP2R413Q in the absence or presence of TNKS2. Whereas WT 3BP2 became polyubiquitylated in the presence of TNKS2, the 3BP2 cherubism mutant poorly incorporated ubiquitin ( Figure 3C, lanes 3 and 4) .
The E3-ubiquitin ligase RNF146 has recently been shown to regulate the Tankyrase-dependent ubiquitylation of Axin2 (Zhang et al., 2011) . RNF146 may be widely employed as an ubiquitin ligase for additional Tankyrase substrates, and we tested whether RNF146 also targets ribosylated 3BP2. We showed that RNF146 binds to 3BP2 but not to a cherubism mutant or to WT 3BP2 in cells in which Tankyrase PARP activity has been inhibited by the Tankyrase-selective inhibitor XAV939 ( Figures 3D and 3E) . Importantly, coexpression of RNF146 abolished the detection of the 3BP2:Tankyrase complex, suggesting that RNF146 might be part of a destruction complex involving 3BP2 and Tankyrase ( Figures 3D and 2E, 2 nd row). Moreover, WT RNF146, but not a mutant form of the ligase lacking its ring finger or the WWE ADP-ribose-binding domain, potently stimulated K48 ubiquitylation of 3BP2 ( Figure 3F ). Depletion of RNF146 in HEK293T cells by three independent interfering RNA hairpin lentiviruses, which efficiently knocked down RNF146 transcript, resulted in increased steady-state levels of 3BP2 ( Figures 3G and S3D ), demonstrating that RNF146 is the functional E3-ligase controlling 3BP2 protein levels.
Elevated Levels of Wild-Type 3BP2 Protein Are Sufficient to Induce Enhanced Osteoclast Formation and TNF-a Secretion by Macrophages Our data demonstrate that cherubism mutations result in the stabilization of 3BP2 protein as a result of loss of repression by Tankyrase. We next asked whether the cherubism-associated characteristics of an in vitro culture of osteoclasts result from elevated 3BP2 levels or from some other neomorphic changes associated with these mutations. We overexpressed WT 3BP2 or the cherubism mutant allele P416R at similar levels using retroviral transduction in the RAW264.7 monocytic cell line, which have osteoclastogenic potential ( Figure 4A ). We observed that overexpression of either WT 3BP2 or the 3BP2P416R cherubism mutant induced the formation of multinucleated Tartrateresistant acid phosphatase (TRAP) positive cells in the absence of RANKL while no multinucleated cells were observed in empty vector-transduced control cells ( Figure 4B) . Moreover, RAW264.7 cells ectopically expressing either WT or a cherubism mutant variant of 3BP2 secreted high levels of TNF-a compared to vector-infected controls ( Figure 4C ). These results demonstrate that elevated levels of WT 3BP2 protein are sufficient to induce enhanced osteoclast formation in the absence of RANKL and increased TNF-a secretion by macrophages consistent with the idea that the basis of cherubsim results from elevated levels of 3BP2 and not due to a neomorphic protein property of the protein.
Enhanced Activation of SRC, SYK, and VAV in Cherubism Osteoclasts 3BP2 nucleates a signaling complex that contains SRC kinases, SYK, and the guanine nucleotide exchange factor VAV (Deckert and Rottapel, 2006) . To understand the effect of 3BP2 stabilization on the signaling pathways that 3BP2 connects to, we examined the phosphorylation levels of SRC, SYK, and VAV as a surrogate of their activation state. SRC, SYK, and VAV were highly tyrosine phosphorylated in osteoclasts derived from Sh3bp2 KI/KI mice compared to osteoclasts from control mice, whereas total SYK, SRC, and VAV protein levels were similar in osteoclasts derived from both mouse strains ( Figure 4D ). To verify that the activities of SRC and SYK were elevated, we performed in vitro kinase assays on both proteins. Both SRC (Figure 4E ) and SYK ( Figure 4F ) autophosphorylation levels were elevated in cherubism osteoclasts compared to normal controls. Similarly, the increased levels of VAV phosphorylation correlated with elevated levels of RAC-GTP in the osteoclasts from cherubism mice as measured by a PAK-CRIB RAC binding pull-down assay ( Figure 4G, lanes 3 and 6) .
TNKS/TNKS2-Depleted Osteoclasts Phenocopy Cherubism Osteoclasts
To test whether the failure of TNKS2-mediated negative regulation of 3BP2 observed in cherubism osteoclasts accounted for their activated phenotype, we examined whether TNKS2-deficient osteoclasts phenocopied cherubism osteoclasts. Wildtype macrophages normally complete osteoclastogenesis in vitro within 5 to 6 days when cultured in RANKL and CSF-1. À/À mice were infected with scrambled shRNA retrovirus (first three rows). BMMs derived from Tnks2 À/À mice were infected with tnks-specific shRNA retrovirus (fourth row). Cells were then grown in CSF-1 (30 ng/ml) and RANKL (5 ng/ml, 10 ng/ml, or 40 ng/ml) for 3 days to initiate osteoclastogenesis, then TRAP stained. Experiments were performed in triplicate. Figure 5A , rows 1-3). Because TNKS and TNKS2 have overlapping essential function during embryonic development (Chiang et al., 2008) , we conjectured that TNKS may also participate in 3BP2 negative regulation in osteoclasts. We observed that both tnks and tnks2 mRNAs are expressed during osteoclast differentiation ( Figure 5B ) and demonstrated that TNKS can bind to and PARsylate 3BP2 when coexpressed in HEK293T cells ( Figures 1E and S4A ). We therefore depleted tnks mRNA in the Tnks2 À/À BMMs using a lentivirus shRNA specific for tnks ( Figure 5C ) and observed that BMMs lacking both TNKS and TNKS2 underwent accelerated osteoclastogenesis closely resembling the activated osteoclast phenotype observed in cherubism osteoclasts ( Figure 5A , row 4). Moreover, we noted that in TNKS/TNKS2-depleted cells, SRC, SYK, and VAV were highly phosphorylated and 3BP2 levels were elevated (Figures 5D, lane 4 and 5E, lane 4, row 4). These results were observed with a second tnks-depleting hairpin lentivirus (data not shown). These data demonstrate that both Tankyrase family proteins participate in the repression of 3BP2 protein levels and the control of SRC, SYK, and VAV activation in macrophages and osteoclasts. Lastly, we observed that WT macrophages depleted of RNF146 similarly underwent accelerated osteoclastogenesis with elevated 3BP2 levels reminiscent of the Sh3bp2 KI/KI or Tankyrase-depleted macrophages (Figures 5F, 5G, and S4B). This effect was dependent on 3BP2 as RNF146 depletion in 3BP2 knockout cells had little effect on in vitro osteoclastogenesis. RNF146 therefore controls osteoclast activity by regulating 3BP2 levels in an ADP-ribose-dependent manner.
Tankyrase Inhibition Promotes Osteoclastogenesis and TNF-a Secretion by Macrophages
To determine whether the activated osteoclast phenotype observed in cells depleted of TNKS/TNKS2 was dependent on 3BP2, we applied the nonselective PARP inhibitor PJ-34 or the recently described TNKS/TNKS2-specific inhibitor IWR-1 (Chen et al., 2009; Huang et al., 2009) to either WT or 3BP2-deficient BMMs cultured under osteoclastogenic conditions. Exposure of WT BMMs to either PJ-34 or IWR-1 resulted in acceleration of osteoclast formation compared to untreated control cells ( Figure 6A , top row). 3BP2-deficient BMMs, however, were completely resistant to the pro-osteoclast effects of either inhibitor ( Figure 6A , bottom row), demonstrating that 3BP2 is the relevant Tankyrase target in these inhibition studies.
Osteoclasts treated with either PJ-34 or IWR-1 exhibited increased levels of phosphorylated SRC, SYK, and VAV and elevated levels of 3BP2 protein compared to control cells ( Figures 6B, lanes 1-3 and 6C, row 4, lanes 1-3) . Moreover, SRC, SYK, and VAV failed to become phosphorylated in cells lacking 3BP2 treated with PARP inhibitors ( Figure 6B , lanes 4-6), demonstrating that 3BP2 is an obligate factor required for SRC pathway activation in osteoclast differentiation. We next tested the effect of Tankyrase inhibition on basal TNF-a production in macrophages. We observed that WT macrophages treated with CSF-1 and IWR-1 for 36 hr secreted 2-fold higher levels of TNF-a compared with vehicle controls ( Figure 6D ) and at levels similar to Sh3bp2 KI/KI -derived macrophages, whereas there was no induction of TNF-a observed in treated Sh3bp2
-derived macrophages. These data provide conclusive evidence that TNKS/TNKS2 negatively regulate the activation of SRC and its downstream targets SYK and VAV in osteoclasts by controlling the abundance of 3BP2. Moreover, genetic depletion or pharmacologic inhibition of Tankyase resulted in an increased response of myeloid cells to CSF-1, an effect phenocopied by the Sh3bp2 KI/KI -derived monocytes.
To test whether SRC activity is required for Tankyrase-and 3BP2-mediated osteoclast differentiation, we applied the SRC inhibitors AZD0530 or PP1 to WT or Sh3bp2 KI/KI -derived macrophages under osteoclastogenic conditions. Incubation with either inhibitor blocked osteoclast formation of both WT and Sh3bp2 KI/KI -derived BMMs ( Figure 6E ). Moreover, addition of these SRC inhibitors to WT BMM cultures treated with the PARP inhibitor IWR-1 similarly blocked osteoclast formation ( Figure 6F Figure S4 . ( Figures S5A-S5C ). The failure of Tnks2 À/À mice to show a cherubism-like phenotype could be the result of the redundant function of TNKS in the hematopoietic compartment. To test whether loss of both TNKS and TNKS2 in the hematopoietc system could recapitulate the cherubism phenotype, we created chimeric mice in which TNKS was knocked down in the Tnks2 À/À background. We depleted TNKS by RNAi-mediated knockdown with a lentivirus harboring a Tnks-specific shRNA in lineagedepleted Tnks2 À/À bone marrow cells (C57Bl/6, CD45.2). Infected bone marrow cells were then injected into lethally irradiated, syngeneic (CD45.1) recipient mice. Wild-type transplantation control chimeric mice were generated from CD45.2-derived bone marrow cells infected with a lentivirus expressing a scrambled shRNA hairpin ( Figure 7A ). Fifteen weeks after transplantation, we evaluated engraftment by measuring the percentage of CD45.2-positive leukocytes in the peripheral blood. Both WT control and TNKS/TNKS2-depleted bone marrow engrafted at similar levels of 38% of peripheral blood leukocytes ( Figure 7B ). TNKS/TNKS2-deficient chimeras showed a trend toward expansion of the CD11b-positive myelomonocytic cells compared to WT chimeras (30% versus 14% of blood leukocytes, respectively; p = 0.16) ( Figure 7C ), suggesting that TNKS/TNKS2 are required to restrain expansion of the myelomonocytic lineage. We then analyzed the trabecular bone volume/total bone volume ratio (BV/TV) of the chimeric mice from each group by microcomputer tomography (mCT).
Relative to the WT chimeric mice, we observed that the TNKS/ TNKS2 chimeric mice had a dramatic reduction in trabecular bone volume of 33% ( Figure 7D ). TRAP staining of tibias of TNKS/TNKS2-deficient chimeras showed a profound increase in TRAP-positive cells compared to WT chimeras (red stain, Figure 7E) . Histomorphometric analysis showed a 2-fold increase in the ratio of osteoclast surface to total bone surface and a 70% increase in osteoclast number per bone surface in TNKS/ TNKS2-deficient chimeras ( Figures 7F and 7G ). We next examined the in vitro culture properties of osteoclasts from both sets of chimeric mice and observed enhanced osteoclastogenesis of BMMs derived from TNKS/TNKS2 chimeric mice, characteristic of the cherubism phenotype ( Figure 7H ). These data provide strong genetic evidence that ablation of TNKS/TNKS2 in vivo phenocopies the hallmark features of bone loss and activated osteoclasts characteristic of cherubism.
DISCUSSION
In this study, we uncover an enzyme-substrate relationship between the PARP Tankyrase and 3BP2, a signaling adaptor protein upstream of SRC kinases, which is mutated in cherubism. Tankyrase-mediated poly(ADP-ribosyl)ation promotes 3BP2 turnover by targeting it to the ubiquitin-proteasome machinery. We show that mutations that give rise to cherubism stabilize 3BP2 and thereby increase its signaling potential to drive osteoclast differentiation characteristic of the cellular dysfunction underlying cherubism. We examined whether cherubism mutations might confer neomorphic properties to 3BP2 that are responsible for the cherubism phenotype. We observed that overexpression of the WT 3BP2 protein was sufficient to induce osteoclast formation (even in the absence of RANKL) and elevated TNF-a secretion in macrophages, two critical features of the cherubism phenotype. These data argue that stabilization of 3BP2 protein is the basis for the hypermorphic behavior of cherubism variants of 3BP2 and provide an explanation for the autosomal-dominant inheritance of the disease. The ability of overexpressed 3BP2 to manifest cherubism-like effects is therefore not likely to be due to a neomorphic property of the protein resulting from these mutations but rather is due to the intrinsic accentuated property of the WT 3BP2 protein. Cherubism mutations reside within a Tankyrase-recruiting peptide motif in 3BP2 and abolish recognition of 3BP2 by Tankyrase. In an accompanying manuscript (Guettler et al., 2011) , we provide a crystal structure of the 3BP2 peptide bound to a TNKS2 ankyrin repeat and determine the general rules for substrate recognition by Tankyrase. It is important to note that all of the known cherubism mutations described to date (Lietman et al., 2006) violate these rules, providing further evidence for the role of disrupted Tankyrase binding as the cause of cherubism. We have highlighted the importance of this interaction by showing that interference with Tankyrase expression or activity in vitro similarly leads to enhanced 3BP2 expression and to hyperactivated osteoclasts and increased TNF-a production by monocytes. Lastly, we have shown that the characteristic cherubism features of bone loss, increased numbers of in situ TRAP-positive osteoclasts, and myelomonocytic expansion can be recapitulated in vivo in TNKS/ TNKS2-deficient bone marrow chimeric mice. These studies have highlighted that 3BP2 is a concentrationlimited factor required for SRC activation in osteoclasts and that modulation of the steady-state levels of 3BP2 tightly controls SRC activity and downstream signaling proteins in these cells. We demonstrated that SRC inhibition blocked osteoclastogenesis associated with cherubism or Tankyrase-inhibited BMMs, suggesting that SRC lies downstream of 3BP2 or is a generally required component for osteoclast formation. These studies also suggest that therapeutic use of SRC kinase inhibitors might benefit cherubism patients.
The biologic function of the Tankyrase proteins is complicated by the multiplicity of identified binding proteins. Mice lacking TNKS or TNKS2 develop normally through embryogenesis. However, adult Tnks À/À mice suffer from a metabolic disorder (Yeh et al., 2009) , whereas Tnks2 À/À mice have a short stature phenotype (Chiang et al., 2006; Hsiao et al., 2006) . Mice lacking both TNKS and TNKS2 die in utero at post-coital day 10, demonstrating that Tankyrase proteins have an essential but redundant function during embryonic development (Chiang et al., 2008) . TNKS was originally identified as a negative regulator of the telomerase inhibitor TRF1/TERF1 (Smith et al., 1998) . TRF1/TERF1 is similarly regulated by ADP-ribosylation and ubiquitin-mediated proteolysis (Chang et al., 2003) . More recently, Tankyrases have been identified as positive regulators of the Wnt/b-catenin pathway through their capacity to negatively regulate AXIN through ADP-ribosylation and ubiquitylation (Huang et al., 2009) . Both TNKS and TNKS2 bind to the mitotic spindle regulator NUMA, but TNKS alone is required for NUMA ribosylation and proper mitotic spindle organization (Chang et al., 2005) . TNKS and TNKS2 bind to a common set of proteins, including insulin-responsive amino peptidase (IRAP), TAB182, and FBP17, all of whom share a common RXXPDG-binding motif that is similar to the 3BP2 Tankyrase-binding peptide sequence mutated in cherubism. In the accompanying manuscript (Guettler et al., 2011), we identify sequence rules for tight binding of targeting peptides by Tankyrase, which may facilitate the identification of previously unknown Tankyrase substrates. Tankyrase inhibition has been proposed as a strategy to treat Wnt-dependent tumors (Huang et al., 2009 ). However, the established role for SRC in controlling osteoclast and macrophage function (Boyce et al., 1992) , in addition to its role in potentiating tumorigenesis, suggests that sustained pharmacologic inhibition of Tankyrase proteins might lead to the untoward effects of osteoporosis, myelomonocytic-mediated inflammation, or tumor promotion. Our studies also raise the possibility that high expression of 3BP2 or loss of function of Tankyrase may contribute to highly active SRC observed in some human cancers (Du et al., 2009; Hynes, 2000; Irby and Yeatman, 2000; Talamonti et al., 1993; Wiener et al., 2003) .
We investigated the manner in which 3BP2 ribosylation is coupled to ubiquitylation. Several distinct PAR-binding motifs have recently been described, including the PAR-binding macrodomain (Karras et al., 2005) , a basic and hydrophobic rich motif capable of PAR recognition present in p53, histones, and XRCC1 (Gagné et al., 2003; Pleschke et al., 2000) , and a poly(ADPribose)-binding zinc finger (PBZ) motif present in the proteins Aprataxin PNK-like factor (APLF) and Checkpoint Protein with FHA and RING domains (CHFR) (Ahel et al., 2008) . Recently, RNF146 has been shown to mediate the ubiquitylation of Axin2 in a ADP-ribose-dependent fashion (Zhang et al., 2011) . We show here that RNF146 binds to 3BP2 but not to cherubism mutants and that binding is dependent on Tankyrase activity. We show that depletion of RNF146 results in the accumulation of 3BP2 and provokes accelerated osteoclastogenesis in a manner observed in cherubism osteoclasts or in osteoclasts lacking Tankyrase proteins. These data identify the E3 ligase RNF146 as a 3BP2-dependent regulator of osteoclast activity. It appears increasingly likely that RNF146 generally recognizes ribosylated Tankyrase substrates.
We have identified ADP-ribosylation as a regulatory switch that controls 3BP2 protein levels as a mechanism to modulate SRC kinase activity and downstream signaling molecules in osteoclasts. The necessity to maintain strict control of the 3BP2/SRC signaling module is underscored in homozygous cherubism mutations in mice, where uncoupling of 3BP2 from Tankyrase-mediated negative regulation results in lethality as a result of systemic myelomonocytic cell infiltration into skin and visceral organs. We have demonstrated that loss of this regulatory pathway is the basis of the molecular mechanism underlying cherubism pathogenesis. Cherubism thus represents an example of a human developmental disease resulting from a defect in ADP-ribosylation.
EXPERIMENTAL PROCEDURES Mice
Sh3bp2
KI/KI mice were a kind gift from Dr. Bjorn Olsen (Harvard School of Medicine, Boston, MA, USA). Derivation of Sh3bp2 À/À mice has been previously described (Chen et al., 2007) . Tnks2 À/À mice were a kind gift from Dr Richard Hodes (National Institutes of Health, Bethesda, MD, USA). Microcomputed Tomography mCT (SkyScan) was performed on tibias of chimeric mice 15 weeks after injection. For details, see the Extended Experimental Procedures.
Chimeric Mice
Bone Marrow Cultures
Nucleated bone marrow cells were purified from mice femora and tibia. Osteoclast differentiation was induced by culturing nonadherent cells in the presence of RANKL and CSF-1. Tartrate-resistant acid phosphatase (TRAP) staining was performed using the Sigma reagent (386A) according to manufacturer protocol. For experiments with bone marrow-derived macrophages, nonadherent cells were cultured for 3 days in the presence of CSF-1. For details, see the Extended Experimental Procedures.
TNF-a ELISA TNF-a in cultured medium was measured using a TNF-a ELISA kit (eBioscience) according to the manufacturer protocol.
Retroviral Transduction
BMMs were infected with PLKO.1 for 48 hr in the presence of 8 mg/ml polybrene (Sigma). Infected cells were selected in puromycin (1.6 mg/ml) for 3 days and then replated for osteoclast differentiation assay. For details, see the Extended Experimental Procedures.
GST-Fusion Peptide Construction and Binding Assay
GST-fusion peptides encompassing either WT or cherubism mutant residues 413-418 of 3BP2 were purified and eluted from glutathione Sepharose beads using standard procedures. HEK293T cells expressing Flag-TNKS2 were lysed, and recombinant GST-3BP2 WT or cherubism peptide fusion proteins were added to the lysates. Tankyrase binding to the GST-3BP2 peptides was then determined by western blot. For details, see the Extended Experimental Procedures.
Immunoprecipitation and Western Blotting
Transfected cells were lysed and precleared with protein A/G Sepharose, then the lysates were incubated with the indicated antibody. For reprecipitation experiments, immune complexes were dissociated in heated 1% SDS buffer cooled and then incubated in 20 mM iodoacetamide prior to dilution with 1 ml of lysis buffer and addition of the secondary antibody for reprecipitation. See the Extended Experimental Procedures. 
